Nucala 100 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FAZLA
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $28,394
Award facts
- Contract value 100% obligated
- $28,393.50 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $28,393.50 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. for NUCALA 100 mg/mL syringes, with an ultimate completion date of September 24, 2025. This delivery order was issued without a set-aside designation and represents a single line item order from DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA, valued at $500 million and valid through November 2026. The contract will be performed in Park Ridge, Illinois, where the woman-owned small business pharmaceutical wholesaler maintains its headquarters.
DMS Pharmaceutical Group serves as a critical supplier within the federal pharmaceutical supply chain, providing branded and generic prescription drugs, biologics, and medical consumables to Department of Defense healthcare facilities. NUCALA (mepolizumab), a biologic medication used for severe eosinophilic asthma, exemplifies the specialty pharmaceutical products the company distributes through its DLA contracts. As a woman-owned small business registered in SAM.gov since 2001, DMS Pharmaceutical Group has built a robust portfolio of federal contract awards across diverse therapeutic categories, from oncology treatments to vaccines and specialty injections, supporting military health facilities nationwide.
Quick answers
Who was awarded contract SPE2DB25FAZLA?
SPE2DB25FAZLA was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 23, 2025.
How much is contract SPE2DB25FAZLA worth?
The government has obligated $28,394 on SPE2DB25FAZLA.
Is contract SPE2DB25FAZLA an order under another contract?
Yes. SPE2DB25FAZLA is a delivery order under SPE2DB24D9222, an indefinite delivery contract.
Was contract SPE2DB25FAZLA competed?
The extent of competition for SPE2DB25FAZLA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award